Heron Therapeuti (HRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heron Therapeuti (HRTX) has a cash flow conversion efficiency ratio of -0.169x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.54 Million) by net assets ($9.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HRTX stock market capitalisation for the company's overall valuation and market capitalisation.
Heron Therapeuti - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Heron Therapeuti's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Heron Therapeuti Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heron Therapeuti ranked by their cash flow conversion efficiency. Explore Heron Therapeuti (HRTX) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suprema ID Inc
KQ:317770
|
0.014x |
|
Mesa Air Group Inc
NASDAQ:MESA
|
0.054x |
|
Mastermyne Group Ltd
AU:MYE
|
0.071x |
|
Gemfields Group Ltd
JSE:GML
|
0.053x |
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
0.041x |
|
MCE Holdings Bhd
KLSE:7004
|
-0.006x |
|
Kedoya Adyaraya Tbk PT
JK:RSGK
|
-0.004x |
|
Wp Energy Public Company Limited
BK:WP
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Heron Therapeuti (1989–2025)
The table below shows the annual cash flow conversion efficiency of Heron Therapeuti from 1989 to 2025. View HRTX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $14.33 Million | $-27.59 Million | -1.925x | -387.53% |
| 2024-12-31 | $-33.65 Million | $-22.53 Million | 0.669x | -61.31% |
| 2023-12-31 | $-33.97 Million | $-58.79 Million | 1.730x | +115.99% |
| 2022-12-31 | $13.57 Million | $-146.91 Million | -10.825x | -312.91% |
| 2021-12-31 | $77.57 Million | $-203.35 Million | -2.622x | -235.45% |
| 2020-12-31 | $236.49 Million | $-184.82 Million | -0.782x | -153.33% |
| 2019-12-31 | $403.83 Million | $-124.58 Million | -0.308x | +40.46% |
| 2018-12-31 | $370.16 Million | $-191.81 Million | -0.518x | +60.10% |
| 2017-12-31 | $131.14 Million | $-170.30 Million | -1.299x | -120.58% |
| 2016-12-31 | $-21.25 Million | $-134.10 Million | 6.310x | +1049.10% |
| 2015-12-31 | $118.11 Million | $-78.53 Million | -0.665x | +30.45% |
| 2014-12-31 | $63.06 Million | $-60.28 Million | -0.956x | -61.68% |
| 2013-12-31 | $68.94 Million | $-40.76 Million | -0.591x | -80.12% |
| 2012-12-31 | $51.82 Million | $-17.01 Million | -0.328x | +33.03% |
| 2011-12-31 | $15.75 Million | $-7.72 Million | -0.490x | +88.24% |
| 2010-12-31 | $1.32 Million | $-5.48 Million | -4.166x | -157.43% |
| 2009-12-31 | $6.80 Million | $-11.00 Million | -1.618x | +49.34% |
| 2008-12-31 | $7.60 Million | $-24.27 Million | -3.195x | -444.92% |
| 2007-12-31 | $29.47 Million | $-17.28 Million | -0.586x | -177.01% |
| 2006-12-31 | $12.06 Million | $9.18 Million | 0.761x | +162.74% |
| 2005-12-31 | $6.20 Million | $-7.53 Million | -1.213x | -121.81% |
| 2004-12-31 | $14.15 Million | $-7.74 Million | -0.547x | +5.57% |
| 2003-12-31 | $11.26 Million | $-6.53 Million | -0.579x | -74.54% |
| 2002-12-31 | $15.46 Million | $-5.13 Million | -0.332x | +1.97% |
| 2001-12-31 | $19.17 Million | $-6.49 Million | -0.339x | -129.91% |
| 2000-12-31 | $21.16 Million | $-3.12 Million | -0.147x | -194.53% |
| 1999-12-31 | $12.00 Million | $-600.00K | -0.050x | +51.67% |
| 1998-12-31 | $14.50 Million | $-1.50 Million | -0.103x | -427.59% |
| 1997-12-31 | $10.20 Million | $-200.00K | -0.020x | +98.39% |
| 1996-12-31 | $5.00 Million | $-6.10 Million | -1.220x | +25.36% |
| 1995-12-31 | $5.20 Million | $-8.50 Million | -1.635x | -124.28% |
| 1994-12-31 | $11.80 Million | $-8.60 Million | -0.729x | +34.59% |
| 1993-12-31 | $10.50 Million | $-11.70 Million | -1.114x | -477.14% |
| 1992-12-31 | $20.20 Million | $-3.90 Million | -0.193x | +83.74% |
| 1991-12-31 | $3.20 Million | $-3.80 Million | -1.188x | -120.04% |
| 1990-12-31 | $6.30 Million | $-3.40 Million | -0.540x | -34.92% |
| 1989-12-31 | $9.50 Million | $-3.80 Million | -0.400x | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more